Latest Myocardial perfusion imaging Stories
BOSTON, June 15 /PRNewswire/ -- FluoroPharma Inc., a company developing breakthrough PET molecular imaging agents, announced that it will present Phase I data relating to the safety, dosimetry, and pharmacokinetics in human subjects of BFPET, its novel 18-F labeled PET tracer for myocardial perfusion imaging, at the Society of Nuclear Medicine 2009 Annual Meeting in Toronto. The results of this study will be presented by Dr.
Physicians should review a patient's computed tomography imaging history and cumulative radiation dose before doing another CT exam, U.S.
Physicians should review a patientâ€™s CT imaging history and cumulative radiation dose when considering whether to perform another CT exam, according to researchers at Brigham and Womenâ€™s Hospital, Boston, MA, and Washington University School of Medicine, St. Louis, MO.
Radiologists can now lower the radiation dose delivered by cardiac CT angiography by 39% in adult patients weighing 185 pounds or less, according to a study performed at the University of Erlangen in Erlangen, Germany.
Physicians can dramatically reduce the radiation dose delivered to patients undergoing coronary CT angiography in a â€œtriple rule-outâ€ protocol by simply using tube current modulation, according to a study performed at Thomas Jefferson University Hospital in Philadelphia, PA.
CT scans are great at helping doctors determine whatâ€™s wrong. But too many of these scans might be promoting illness rather than helping to diagnose it.
A lifetime of computed tomography -- detailed X-ray images of internal organs -- may increase cancer risks for some patients, U.S. researchers say. CT is an excellent diagnostic tool of tremendous clinical value in many situations, Dr.
Nuclear medicine procedure is still the best predictor of event-free survival, according to article in The Journal of Nuclear Medicine.
Patients who undergo numerous CT scans over their lifetime may be at increased risk for cancer, according to a study published in the April issue of Radiology.
Acusphere, Inc. (NASDAQ: ACUS) announced that additional analyses from its Phase 3 clinical trials of Imagify(TM) (Perflubutane Polymer Microspheres) for Injectable Suspension were presented today at the annual American Heart Association Scientific Sessions in New Orleans, Louisiana.